2013 half-year activity
(Unaudited data)
. CUMULATIVE ACTIVITY AS OF THE END OF JUNE 2013
In thousands of euros
2012
2013
Variation at current exchange rates
Variation at constant exchange rates
France
145,398
159,597
+9.8%
+9.8%
International :
96,120
116,187
+20.9%
+21.8%
Incl. Europe (excluding France)
70,696
83,381
+17.9%
+18.5%
Incl. North America
20,146
25,579
+27.0%
+28.8%
Incl. Other countries
5,278
7,227
+36.9%
+39.9%
Group Total
241,518
275,784
+14.2%
+14.6%
In thousands of euros
2012
2013
Variation at current exchange rates
Variation at constant exchange rates
Non-proprietary Homeopathic Medicines
143,633
152,097
+5.9%
+6.0%
OTC Specialties
97,583
123,466
+26.5%
+27.3%
Other
302
221
-26.8%
-28.1%
Group Total
241,518
275,784
+14.2%
+14.6%
. ACTIVITY IN THE QUARTER (variation at current rate)
In thousands of euros
1st Quarter
2nd Quarter
2012
2013
Var.
2012
2013
Var.
France
74,188
84,270
+13.6%
71,210
75,327
+5.8%
International :
54,904
73,751
+34.3%
41,216
42,436
+3.0%
Incl. Europe (excluding France)
41,807
54,334
+30.0%
28,889
29,047
+0.5%
Incl. North America
10,285
15,562
+51.3%
9,861
10,017
+1.6%
Incl. Other countries
2,812
3,855
+37.1%
2,466
3,372
+36.7%
Group Total
129,092
158,021
+22.4%
112,426
117,763
+4.7%
In thousands of euros
1st Quarter
2nd Quarter
2012
2013
Var.
2012
2013
Var.
Non-proprietary Homeopathic Medicines
73,427
79,062
+7.7%
70,206
73,035
+4.0%
OTC Specialties
55,576
78,866
+41.9%
42,007
44,600
+6.2%
Other
89
93
+4.5%
213
128
-39.9%
Group Total
129,092
158,021
+22.4%
112,426
117,763
+4.7%
2013 SECOND QUARTER HIGHLIGHTS
After a growth by 22.4% in the first quarter due notably to the strong pathology, sales revenue in the second quarter increased by 4.7% at current exchange rate (+5.2% at constant exchange rate).
Unda has announced its attention to reorganize its activities in order to ensure the development of homeopathy in Belgium. This project, likely to have social effects on the two Belgian sites, could affect around 60 employees over 194.
In the United States, the settlement agreement aimed to put an end to the legal proceeding relating to Children's Coldcalm® medicine in California obtained the prior approval of the Los Angeles court. Boiron USA is awaiting the court's final approval of the agreement. A provision of one million US dollars was recorded in the accounts as of December 31, 2011, which we still believe is corresponding to the risk incurred.
On June 30, 2013, the cash position of the group is exceeding 100 million euros against 94.7 million euros on December 31, 2012.
The half-year profitability should be in noticeable progress. In support of these performances, the group confirms targeting a new increase of its activity and profitability in 2013.
Our next update:
August 29, 2013: at market close, publication of 2013 half-year results.
Person responsible for financial information: Philippe MONTANT
Contact for financial information: Véronique BOUSCAYROL
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : finances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA
The group's financial information is online at: www.boiron.com
Communiqués au titre de l'obligation d'information permanente :
- Communiqué sur comptes, résultats, chiffres d'affaires
Communiqué intégral et original au format PDF :
http://www.actusnews.com/documents_communiques/ACTUS-0-32800-boi-120713-ca-t2-13-gb.pdf
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
Quelle: Actusnews